Month: September 2020

GUANGZHOU, China, Sept. 17, 2020 (GLOBE NEWSWIRE) — Puyi Inc. (“Puyi” or the “Company”) (NASDAQ: PUYI), a leading third-party wealth management service provider in China focusing on mass affluent and emerging middle class population, today announced that it will release its audited financial results for the fiscal year 2020 ended June 30, 2020 on September 28, 2020.Senior management will host a combined English and Chinese language conference call to discuss the Company’s audited financial results and business development for fiscal year 2020 ended June 30, 2020.Dial-in details for the conference call are as follows:Conference ID #: 5983079The conference call will be a Direct Event call, which requires online registration in advance. Please use the link http://apac.directeventreg.com/registration/event/5983079 to complete the online...

62% 2-year OS; median OS not reachedStable, non-overlapping safety profileClinical synergy between PV-10 and immune checkpoint blockadeData compare favorably to approved therapies for patient populationKNOXVILLE, TN, Sept. 17, 2020 (GLOBE NEWSWIRE) — Provectus (OTCQB: PVCT) today announced that 2-year landmark survival, response, and safety data from the Company’s Phase 1b/2 study of small molecule autolytic cancer immunotherapy PV-10, an injectable formulation of Provectus’ proprietary rose bengal disodium (RBD), in combination with KEYTRUDA (pembrolizumab) for the treatment of advanced cutaneous melanoma in patients naïve to immune checkpoint blockade (CB) will be presented at the European Society for Medical Oncology (ESMO) Virtual Congress 2020, held online from September 19-21, 2020.Intralesional (IL) (aka intratumoral) administration...

– Maintained 34% objective response rate and 79% disease control rate, including two complete responses – XMT-1536 continues to be generally well-tolerated with no new safety signals– Data to be presented and discussed during a conference call today at 8 a.m. ETCAMBRIDGE, Mass., Sept. 17, 2020 (GLOBE NEWSWIRE) — Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today reported updated interim safety, tolerability and efficacy data for the ovarian cancer cohort of the ongoing expansion portion of the Phase 1 study evaluating XMT-1536, its first-in-class ADC candidate targeting NaPi2b, as part of the 2020 European Society of Medical Oncology (ESMO)...

Woulo Woulo prospect returns 1.64 g/t gold over 80.5 metres and 1.97 g/t gold over 41 metres(All amounts are in U.S. dollars unless otherwise stated)TORONTO, Sept. 17, 2020 (GLOBE NEWSWIRE) — Teranga Gold Corporation (“Teranga” or the “Company”) (TSX: TGZ, OTCQX:TGCDF) is pleased to announce extensive gold mineralization starting at surface, numerous high-grade gold intercepts and a new discovery at the Woulo Woulo prospect from Teranga’s initial drill results at its Afema exploration project (“Afema”) in southeastern Côte d’Ivoire (Figure 1 in Appendix B).Afema covers more than 1,400 km2, consisting of the Afema mining license and three exploration permits – Ayame, Mafere and Aboisso (Figure 2 in Appendix B). The Afema mine license has a historical near-surface oxide and sulphide resource within an area...

HANGZHOU, China, Sept. 17, 2020 (GLOBE NEWSWIRE) — Ruhnn Holding Limited (“ruhnn” or the “Company”) (NASDAQ: RUHN), a leading internet key opinion leader (“KOL”) facilitator in China, today announced its participation in the following investor conferences:ICA Asia Insights Forum, September 23, 2020, Virtual Zhitong Caijing China Concept Stock Summit, September 24, 2020, Hangzhou, ChinaThe Company’s management will meet with institutional investors throughout these events. For additional information, please contact event organizers.About Ruhnn Holding LimitedRuhnn Holding Limited is a leading internet key opinion leader (“KOL”) facilitator in China. The Company connects influential KOLs who engage and impact their fans on the internet to its vast commercial network to build the brands of fashion products. Ruhnn pioneered the commercialization...

Roblon’s full-year guidance for 2019/20 maintainedInterim report – Q3 2019/20 (the period 1 November 2019 – 31 July 2020)

Forventningerne til Roblons 2019/20-resultat fastholdesDelårsrapport for 3. kvartal af 2019/20 (perioden 1. november 2019 – 31. juli 2020)Bestyrelsen for Roblon A/S har i dag behandlet og godkendt koncernens delårsrapport for 3. kvartal af regnskabsåret 2019/20Hovedpunkter i delårsrapporten for Roblon-koncernenOrdretilgangen blev 196,7 mDKK (204,2 mDKK). Der er vækst i produktgruppen FOC, mens der har været tilbagegang i produktgruppen Composite.Ordrebeholdning pr. 31. juli 2020 blev 28,2 mDKK (83,1 mDKK), og tilbagegangen vedrører væsentligst produktgruppen Composite.Koncernens nettoomsætning har som forventet været negativt påvirket af udbrud af COVID-19 i 3. kvartal af 2019/20. Nettoomsætningen androg 204,8 mDKK (173,0 mDKK).Bruttomargin steg til 54,5% (41,0%) primært som følge af et bedre produktmix, ligesom sidste år var negativt...

Attached your will find information about payments for Havi04 and Havi07 on due date 30.09.20Contact:CFO Arne Johan Dale, +47 909 87 706This information is subject to the disclosure requirements pursuant to Section 5-12 the Norwegian Securities Trading ActAttachmentsHavi04 Q320Havi07 Q320

Share Buyback Transaction Details September 10 – 16, 2020September 17, 2020 – Wolters Kluwer today reports that it has repurchased 109,833 of its own ordinary shares in the period from September 10, 2020, up to and including September 16, 2020, for €7.9 million and at an average share price of €71.92.These repurchases are part of the share buyback program announced on February 26, 2020, under which we intend to repurchase shares for up to €350 million during 2020.The cumulative amounts repurchased to date under this program are as follows:Share Buyback 2020For the period starting August 6, 2020, up to and including October 28, 2020, we have engaged a third party to execute €100 million of buybacks on our behalf, within the limits of relevant laws and regulations (in particular Regulation (EU) 596/2014) and the company’s Articles...

Mainz, Germany, Sept. 17, 2020 (GLOBE NEWSWIRE) —Facility will become one of the largest mRNA manufacturing sites in Europe and the third site in the BioNTech manufacturing network in Germany expected to produce BNT162 for global supplyExpected to be fully operational in the first half 2021 with an annual production capacity up to 750 million doses of potential COVID-19 vaccineRapid transition expected due to well-established biotechnology drug substance and drug product manufacturing equipment as well as an experienced teamBioNTech will take over the entire site with currently approximately 300 employees, enabling a rapid transition to BNT162 production upon transaction closing             MAINZ, Germany, September 17, 2020 (GLOBE NEWSWIRE) – BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) today announced the signing of...